Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation

Scientists at King’s College London have identified a promising new strategy to combat Alzheimer’s disease that could tackle several of the condition’s devastating effects simultaneously. Their research shows that an experimental drug developed for spinal cord injury can help repair damaged DNA, reduce inflammation, and target biological changes associated with the disease.
The drug, known as KCL-286, produced promising results in a mouse model of Alzheimer’s disease. Unlike treatments that focus primarily on the formation of toxic proteins in the brain, this approach targets additional processes that may begin long before the disease reaches its advanced stages.
Another promising advantage is that KCL-286 has already completed a Phase 1 human safety and tolerability trial as part of its early development. This could greatly shorten the path to further clinical trials, although its effectiveness against Alzheimer’s in humans has not been established.
“KCL-286 is a first-in-class, orally bioavailable small molecule that has already successfully cleared Phase 1 of human safety and tolerability testing. This will significantly reduce the multi-year timeline required for new drug development,” commented Professor Jonathan Corcoran, Professor of Neuroscience at the Institute of Psychiatry, Psychology’s King Neuro College in London.
The drug is a small molecule that can be taken orally, making it easier to use than treatments that require injections or infusions.
Why Alzheimer’s Disease Is So Hard to Treat
Alzheimer’s disease involves a complex series of changes in the brain, making it particularly challenging to develop effective treatments. Two of its best-known features are the abnormal accumulation of proteins called amyloid-beta and tau.
Amyloid-beta can accumulate into sticky deposits between nerve cells, while abnormal tau proteins form tangles within them. These changes disrupt normal brain function and are associated with progressive loss of neurons, specialized cells responsible for transmitting information throughout the brain.
Much of the effort to develop Alzheimer’s treatments is focused on these two proteins. Although drugs that remove amyloid-beta have shown modest but measurable clinical benefits, they do not fully address the many biological processes involved in the disease.
Researchers are increasingly investigating other changes that may contribute to Alzheimer’s, including DNA damage and brain inflammation. Both can appear early in the disease process, making them potentially important targets for treatments designed to slow its progression.
In a new study, KCL-286 helped repair breaks in DNA and reduce inflammation in mice with Alzheimer’s disease. These findings suggest that targeting several risk processes simultaneously may provide a more comprehensive approach than focusing on amyloid-beta or tau alone.
“Our findings show that KCL-286 not only targets DNA damage but also reduces inflammation, two processes that occur early in Alzheimer’s disease. This highlights its potential as a disease-modifying treatment rather than just addressing symptoms,” said Dr. Maria Goncalves, who managed the drug development project.
How Vitamin A Can Help Fight Alzheimer’s
The drug works by activating a specific protein involved in the retinoic acid pathway, a biological system associated with how the body works and uses vitamin A.
Vitamin A is best known for supporting healthy vision, but it also plays an important role in cell development, gene regulation, and nervous system function. Retinoic acid, a substance found in vitamin A, helps regulate the activity of genes involved in several important biological processes.
Previous research has found that disruptions in this pathway were associated with the formation of amyloid-beta deposits in the brains of mice. These funds are similar to a major pathological feature of Alzheimer’s, suggesting that the mechanism may be relevant to this condition.
KCL-286 activates a specific protein within this system, giving researchers a way to influence biological processes linked to brain health and cellular repair.
The drug had already shown the ability to promote the repair of DNA double-strand breaks in previous studies involving neuropathic pain, a type of pain caused by damage or dysfunction in the nervous system.
That discovery led scientists to investigate whether a similar approach could help deal with the DNA damage associated with Alzheimer’s disease.
Repairing a Dangerous Type of DNA Damage
DNA contains the genetic instructions that cells need to function properly. Although cells have natural mechanisms to repair damaged DNA, some types of damage are more serious.
One example is DNA double-strand break, which occurs when both strands of a DNA molecule are separated. These breaks can interfere with normal cellular function and threaten cell survival if not properly repaired.
“DNA double-strand breaks are like a strand that breaks completely in two, rather than just fraying at the ends. We found that KCL-286 promotes the repair of these breaks, allowing us to look at an important feature of Alzheimer’s disease,” said Professor Corcoran.
Researchers had another reason to suspect that KCL-286 might be useful against Alzheimer’s. Previous work by the same group at King’s College London identified molecular mechanisms shared by acute spinal cord injury and Alzheimer’s disease.
Because these two conditions involve some overlapping biological mechanisms, scientists believe that a drug designed to deal with damage to the nervous system after a spinal cord injury may improve certain Alzheimer’s-related changes in neurons.
Their new findings support that possibility, showing that KCL-286 can affect multiple cellular pathways involved in the disease.
A Promising New Guide to Alzheimer’s Treatment
The results highlight a potentially important change in Alzheimer’s research. Rather than focusing on one type of the disease, scientists are exploring treatments that address several interconnected causes of brain damage.
KCL-286 is particularly interesting because it targets DNA damage and inflammation, two processes that can appear early in the progression of Alzheimer’s. Its early human safety assessment provides a potential benefit to entirely new drug candidates that have yet to enter clinical development.
However, the findings of Alzheimer’s are still clinical. More studies and clinical trials in humans will be needed to determine whether the drug can safely slow the progression of the disease or improve outcomes for patients.
Natasha Hill, one of the first authors on the paper, said: “To develop an effective treatment for Alzheimer’s disease, we need to address many aspects of the disease. KCL-286 was able to target many cellular pathways associated with the disease, some of which are activated early in the course of the disease.”
Source link


